期刊文献+

RP-HPLC测定雷诺嗪含量及有关物质 被引量:9

Quantification of ranolzaine and its relevant substances by RP-HPLC
下载PDF
导出
摘要 目的:建立测定雷诺嗪(ranolazine)含量及有关物质的反相高效液相色谱法。方法:依利特Hypersil BDS C_(18)硅烷键合硅胶柱(250mm×4.6mm,5μm),流动相:甲醇-7mmol·L^(-1)醋酸铵与3.5mmol·L^(-1)醋酸的缓冲液(65:35),流速:1.0mL·min^(-1),柱温:30℃,检测波长:272nm。结果:雷诺嗪在0.102~2.034mg·mL^(-1)的范围内,浓度和峰面积线性良好,r=0.9999。重复性试验的RSD为0.92%。结论:测定方法简便快速、重现性好、准确度高,可适用于雷诺嗪的含量测定及其有关物质检查。 Objective:To establish a RP-HPLC method for the quantification of ranolazine and its relevant substances. Methods; The RP-HPLC conditions was as followed: a Hypersil BDS C18 column (250 mm×4.6 mm,5μm) with a column temperature at 30℃ a mobile phase consisted of methanol-7mmol·L^-1 ammonium acetate : 3.5mmol·L^-1 acetic acid (65 : 35 ) with a flow rate of 1.0 mL·min^-1 and a detection wavelength at 272.nm. Results:The linearity of ranolazine concentration was within 0. 102 ~ 2. 034mg·mL^-1 ( r = 0. 999 9) with RSD of 0.92%. Conclusion : The reliable and rapid RP-HPLC method to quantify ranolazine and its relevant is achievable.
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第14期1190-1192,共3页 Chinese Journal of New Drugs
关键词 雷诺嗪 反相高效液相色谱法 含量测定 ranolazine RP-HPLC quantification
  • 相关文献

参考文献3

二级参考文献25

  • 1Eva AC, Tibor G, Kalman H. Process for the preparation of piperazine derivatives [ P]. EP: 0483932 A1,1991 - 10- 31.
  • 2McCormack JG, Stanley WC, Wolff AA. Ranolazine, a novel metabolic modulator for the treatment of angina[J]. Gen Pharm, 1998, 30(5) :639 - 645.
  • 3Zacharowski K, Lackburn BB, Thiemeermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat [ J ]. Eur J Pharmacol, 2001, 418 (1 - 2) : 105 -110.
  • 4Mcaroon J, Clark RD, Kluge AF, et al. Synthesis and antihypertensive activity of a series of 8-aubalituted 1-oxa-3, 8-diazaspiro [ 4. 5 ] decan-2-ones [ J ]. J Med Chem, 1981,24(11) : 1320 - 1328.
  • 5Kluge AF, Clark RD, Strosberg AM, et al. Cardioselective aryloxy-and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry[P]. US:4567264,1986 - 01 - 28.
  • 6Schofield RS, Hill JA. The uee of ranolazine in cardiovascular disease[J].Expert Opin Investig Drugs,2002,11(1):117-123
  • 7Wolff AA, Rotmensch HH.Metabolic approaches to the treatment of ischemic heart disease:the clinicians'perspective[J].heart Fail Rev,2002,7(2):187-203
  • 8McCormack JG, Barr RL.Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts[J]. Circulation, 1996, 93(1):135- 142.
  • 9Clarke B, Wyatt KM, McCormack JG.Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism[J]. J Mol Cell Cardiol, 1996, 28(2):341-350.
  • 10Allen TJ,Chapman RA.Effects of ranolazine on L-type calcium channel currents in guinea-pig single wentricular myocytes[J].Br J Pharmacol,1996,118(2):249-254

共引文献21

同被引文献2140

引证文献9

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部